AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alnylam Pharmaceuticals CEO Yvonne Greenstreet buys and sells shares.
ByAinvest
Tuesday, Jun 3, 2025 4:17 pm ET1min read
Alnylam Pharmaceuticals Inc. (ALNY) has announced that Yvonne Greenstreet, Director and Chief Executive Officer, has made several transactions involving the purchase and sale of shares. Specifically, on May 30, 2025, Greenstreet acquired 19,559 shares at $118.05 per share, while also selling 6,171 shares at $306 per share. Additionally, on June 2, 2025, she sold 19,297 shares at $306 per share, and purchased 12,081 shares at $119.13 per share. Furthermore, on June 2, 2025, Greenstreet acquired 12,080 shares at $119.13 per share and 7,217 shares at $118.05 per share. Finally, on May 30, 2025, she sold 25,469 shares at $304 per share.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet